Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis

American Journal of Rhinology and Allergy

Volumn 23, Issue 1, 2009, Pages 46-51

  Chennupati, Sri Kiran ^a   Chiu, Alexander G ^a   Tamashiro, Edwin ^a,b   Banks, Caroline A ^a   Cohen, Michael B ^a   Bleier, Benjamin S ^a   Konofow, Jennifer M ^b   Tam, Eric ^b   Cohen, Noam A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Animal model; Antimicrobial peptide; Biofilm; Cathelicidin; LL 37; Pseudomonas; Sinusitis; Topical therapies

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOFILM; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL RABBIT; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; LAVAGE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOSE MUCOSA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SCANNING ELECTRON MICROSCOPY; SINUSITIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIPOPOLYSACCHARIDES; MAXILLARY SINUSITIS; NASAL LAVAGE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; TREATMENT OUTCOME;

EID: 70149113165     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2009.23.3261     Document Type: Article

References (42)

1. Bendouah Z, Barbeau J, Hamad WA, and Desrosiers M. Biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa is associated with an unfavorable evolution after surgery for chronic sinusitis and nasal polyposis. Otolaryngol Head Neck Surg 134:991-996, 2006.
2. Cryer J, Schipor I, Perloff JR, and Palmer JN. Evidence of bacterial biofilms in human chronic sinusitis. ORL J Otorhinolaryngol Relat Spec 66:155-158, 2004.
3. Ferguson BJ, and Stolz DB. Demonstration of biofilm in human bacterial chronic rhinosinusitis. Am J Rhinol 19:452-457, 2005.
4. Costerton JW, Stewart PS, and Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 284: 1318-1322, 1999.
5. Stewart PS, and Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138, 2001.
6. Ceri H, Olson, ME, Stremick C, et al. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776, 1999.
7. Whatley WS, Chandra RK, and MacDonald CB. Systemic absorption of gentamicin nasal irrigations. Am J Rhinol 20: 251-254, 2006.
8. De Smet K, and Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27: 1337-1347, 2005.
9. Altman H, Steinberg D, Porat Y, et al. In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J Antimicrob Chemother 58:198-201, 2006.
10. Hider RC. Honeybee venom: A rich source of pharmacologically active peptides. Endeavour 12:60-65, 1988.
11. Maher S, and McClean S. Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem Pharmacol 71:1289-1298, 2006.
12. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248, 2002.
13. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-660, 1997.
14. Johansson J, Gudmundsson GH, Rottenberg ME, et al. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273:3718-3724, 1998.
15. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192:1069-1074, 2000.
16. Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106:20-26, 2002.
17. Nell MJ, Tjabringa GS, Wafelman AR, et al. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27:649-660, 2006.
18. Perloff JR, and Palmer JN. Evidence of bacterial biofilms on frontal recess stents in patients with chronic rhinosinusitis. Am J Rhinol 18:377-380, 2004.
19. Perloff JR, and Palmer JN. Evidence of bacterial biofilms in a rabbit model of sinusitis. Am J Rhinol 19:1-6, 2005.
20. Antunes MB, Feldman MD, Cohen NA, and Chiu AG. Dose-dependent effects of topical tobramycin in an animal model of Pseudomonas sinusitis. Am J Rhinol 21:423-427, 2007.
21. Chiu AG, Antunes MB, Feldman M, and Cohen NA. An animal model for the study of topical medications in sinusitis. Am J Rhinol 21:5-9, 2007.
22. Chiu AG, Antunes MB, Palmer JN, and Cohen NA. Evaluation of the in vivo efficacy of topical tobramycin against Pseudomonas sinonasal biofilms. J Antimicrob Chemother 59:1130-1134, 2007.
23. Ooi EH, Wormald PJ, Carney AS, et al. Human cathelicidin antimicrobial peptide is up-regulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients. Am J Rhinol 21:395-401, 2007.
24. Murakami M, Ohtake T, Dorschner RA, and Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 81:845-850, 2002.
25. Murakami M, Ohtake T, Dorschner RA, et al. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 119:1090-1095, 2002.
26. Kim ST, Cha HE, Kim DY, et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 123:81-85, 2003.
27. Carothers DG, Graham SM, Jia HP, et al. Production of beta-defensin antimicrobial peptides by maxillary sinus mucosa. Am J Rhinol 15:175-179, 2001.
28. Ooi EH, Wormald PJ, and Tan LW. Innate immunity in the paranasal sinuses: A review of nasal host defenses. Am J Rhinol 22:13-19, 2008.
29. Ramadan HH, Sanclement JA, and Thomas JG. Chronic rhinosinusitis and biofilms. Otolaryngol Head Neck Surg 132:414-417, 2005.
30. Sanclement JA, Webster P, Thomas J, and Ramadan HH. Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope 115:578-582, 2005.
31. Sanderson AR, Leid JG, and Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 116:1121-1126, 2006.
32. Psaltis AJ, Ha KR, Beule AG, et al. Confocal scanning laser microscopy evidence of biofilms in patients with chronic rhinosinusitis. Laryngoscope 117:1302-1306, 2007.
33. Prince AA, Steiger JD, Khalid AN, et al. Prevalence of biofilm forming bacteria in chronic rhinosinusitis. Am J Rhinol 22:239-245, 2008.
34. Psaltis AJ, Weitzel EK, Ha KR, and Wormald PJ. The effect of bacterial biofilms on post-sinus surgical outcomes. Am J Rhinol 22:1-6, 2008.
35. Ha KR, Psaltis AJ, Butcher AR, et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope 118:535-540, 2008.
36. Desrosiers M, Myntti M, and James G. Methods for removing bacterial biofilms: In vitro study using clinical chronic rhinosinusitis specimens. Am J Rhinol 21:527-532, 2007.
37. Tamashiro E, Banks CA, Chen B, et al. In vivo effects of citric acid/ zwitterionic surfactant (CAZS) cleansing solution on sinus mucosa. Am J Rhinol In press.
38. Schipor I, Cryer JE, Cohen AS, et al. Physiologic sequelae of biofilm and non-biofilm forming Pseudomonas aeruginosa sinusitis. Combined Otolaryngolgy Spring Meeting, Boca Raton, FL, 2005.
39. Al-Rawi MM, Edelstein DR, and Erlandson RA. Changes in nasal epithelium in patients with severe chronic sinusitis: A clinicopathologic and electron microscopic study. Laryngoscope 108:1816-1823, 1998.
40. Toskala E, Nuutinen J, and Rautiainen M. Scanning electron microscopy findings of human respiratory cilia in chronic sinusitis and in recurrent respiratory infections. J Laryngol Otol 109:509-514, 1995.
41. Keles N, Ahishali B, Ilicali OC, and Deger K. Evaluation of ultrastructural changes in paranasal sinus mucosa after functional endoscopic sinus surgery in patients with chronic rhinosinusitis. Am J Rhinol 15:225-229, 2001.
42. Chen B, Shaari J, Claire SE, et al. Altered sinonasal ciliary dynamics in chronic rhinosinusitis. Am J Rhinol 20:325-329, 2006.